10x Genomics, Inc. (TXG) Revenue History
Annual and quarterly revenue from 2017 to present
TXG Revenue Over Time (2017–2025)
TXG Revenue Growth History
7 of 8 years with positive growth- FY2017 revenue growth
- N/A
- FY2018 revenue growth
- +105.8%
- FY2019 revenue growth
- +68.1%
- FY2020 revenue growth
- +21.5%
- FY2021 revenue growth
- +64.1%
- FY2022 revenue growth
- +5.3%
- FY2023 revenue growth
- +19.8%
- FY2024 revenue growth
- -1.3%
- FY2025 revenue growth
- +5.2%
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $150.8M | -2.6% |
| Q4 2025 | $166.0M | +0.6% |
| Q3 2025 | $149.0M | -1.7% |
| Q2 2025 | $172.9M | +12.9% |
| Q1 2025 | $154.9M | +9.8% |
| Q4 2024 | $165.0M | -10.3% |
| Q3 2024 | $151.7M | -1.3% |
| Q2 2024 | $153.1M | +4.3% |
Multi-year avg. share of annual revenue by fiscal quarter
Revenue Breakdown (FY 2025)
TXG's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
TXG Revenue Analysis (2017–2025)
Current Revenue & Growth
As of June 22, 2026, 10x Genomics, Inc. (TXG) generated trailing twelve-month (TTM) revenue of $638.8 million, reflecting slight decline in growth of -2.6% year-over-year. The most recent quarter (Q1 2026) recorded $150.8 million in revenue, down 9.1% sequentially.
Historical Growth Trajectory
TXG's 5-year compound annual growth rate (CAGR) stands at +16.6%, indicating consistent double-digit revenue growth. The 3-year CAGR of +7.6% is below the 5-year average, signalling a growth deceleration in recent years. 10x Genomics, Inc.'s highest annual revenue of $642.8 million was recorded in 2025, an all-time high.
Revenue by Segment
TXG's revenue is primarily driven by Product And Service Revenue (48%), Consumables (41%), and Instruments (5%). The diversified mix across segments reduces dependence on any single product line, which can support more resilient revenue in downturns.
Peer Comparison
Compared to Healthcare sector peers — including PACB (+5.0% YoY), ILMN (+1.2% YoY), and BRKR (+0.4% YoY) — TXG has underperformed the peer group in revenue growth. Compare TXG vs PACB →
TXG Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| TXGCurrent | $639M | -2.6% | +16.6% | -17.2% | |
 PACB | $160M | +5.0% | +15.2% | -348.5% | |
 ILMN | $4.3B | +1.2% | +6.0% | 19.9% | |
 BRKR | $3.4B | +0.4% | +11.6% | 6.9% | |
 FLGT | $323M | +13.8% | -5.2% | -28.2% | |
 CDNA | $380M | +19.2% | +14.6% | -5.5% |
TXG Historical Revenue Data (2017–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $642.8M | +5.2% | $443.9M | 69.1% | $-110,885,000 | -17.2% |
| 2024 | $610.8M | -1.3% | $414.5M | 67.9% | $-194,559,000 | -31.9% |
| 2023 | $618.7M | +19.8% | $409.3M | 66.2% | $-265,329,000 | -42.9% |
| 2022 | $516.4M | +5.3% | $396.0M | 76.7% | $-167,944,000 | -32.5% |
| 2021 | $490.5M | +64.1% | $416.4M | 84.9% | $-52,913,000 | -10.8% |
| 2020 | $298.8M | +21.5% | $240.4M | 80.4% | $-85,324,000 | -28.6% |
| 2019 | $245.9M | +68.1% | $184.9M | 75.2% | $-29,071,000 | -11.8% |
| 2018 | $146.3M | +105.8% | $117.7M | 80.4% | $-110,764,000 | -75.7% |
| 2017 | $71.1M | - | $60.5M | 85.1% | $-18,375,000 | -25.8% |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
9+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
TXG — Frequently Asked Questions
Quick answers to the most common questions about buying TXG stock.
Is TXG's revenue growth accelerating or slowing?
TXG revenue growth is slowing. TTM revenue is $639M, up -2.6% year-over-year — below the 5-year CAGR of +16.6%. The deceleration suggests maturing end-markets or increased competition.
What is TXG's revenue history from 2017 to 2026?
10x Genomics, Inc. (TXG) revenue history spans 2017 to 2026. TTM revenue as of 2026 is $639M, growing at -2.6% YoY. The 5-year CAGR is +16.6%. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is TXG's long-term revenue growth rate (CAGR)?
10x Genomics, Inc.'s 5-year revenue CAGR of +16.6% reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of -2.6% is below this long-term average. CAGR is the most reliable measure of sustained revenue momentum for TXG.
Why does TXG's quarterly revenue fluctuate?
TXG quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. 10x Genomics, Inc.'s revenue data from 2017 to 2026 shows full historical quarterly detail on this page.
How is TXG's revenue distributed by segment?
TXG reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does TXG's revenue compare to industry peers?
10x Genomics, Inc. (TXG) with TTM revenue of $639M and -2.6% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.